Literature DB >> 25639558

Celiac disease evolving into dermatitis herpetiformis in patients adhering to normal or gluten-free diet.

Teea T Salmi1, Kaisa Hervonen, Kalle Kurppa, Pekka Collin, Katri Kaukinen, Timo Reunala.   

Abstract

OBJECTIVE: Dermatitis herpetiformis (DH) is a cutaneous form of celiac disease affecting ∼ 17% of celiac disease patients. The aim was to determine how often celiac disease precedes the development of DH, and what is the impact of gluten-free diet (GFD) in this phenotype change.
MATERIAL AND METHODS: Our prospectively collected DH series from 1970 comprised 514 patients. We analyzed all DH patients who at least 2 years earlier had been diagnosed with celiac disease. DH diagnosis was confirmed by showing immunoglobulin A deposits in dermis. Serological and small bowel mucosal findings were analyzed, and the strictness of GFD treatment before and after the diagnosis of DH was evaluated.
RESULTS: Twenty (4%) DH patients had a prior diagnosis of celiac disease. The median time interval between celiac disease and DH detection was 9.5 years. Before DH appeared 4 patients had been on a normal gluten-containing diet, 10 had dietary lapses on a GFD, and 6 were on a strict GFD. Celiac autoantibodies were positive in 7 out of 19 patients, and 5 out of 7 undergoing small bowel biopsy had partial villous atrophy. Following DH diagnosis the rash was controlled after a median of 6 months on a strict GFD.
CONCLUSIONS: Patients with celiac disease may develop DH by time. This is most often an indicator of poor adherence to GFD, and a rigorous dietary intervention is necessary. In the majority of cases, DH will be detected without prior celiac disease diagnosis, but the physicians should recognize this phenotype alteration.

Entities:  

Keywords:  celiac disease; dermatitis herpetiformis; follow-up; gluten-free diet

Mesh:

Substances:

Year:  2015        PMID: 25639558     DOI: 10.3109/00365521.2014.974204

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

Review 1.  Current Concepts of Dermatitis Herpetiformis.

Authors:  Teea Salmi; Kaisa Hervonen
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

Review 2.  Extraintestinal Manifestations of Celiac Disease: Early Detection for Better Long-Term Outcomes.

Authors:  Pilvi Laurikka; Samuli Nurminen; Laura Kivelä; Kalle Kurppa
Journal:  Nutrients       Date:  2018-08-03       Impact factor: 5.717

Review 3.  Dermatitis Herpetiformis: An Update on Diagnosis and Management.

Authors:  Timo Reunala; Kaisa Hervonen; Teea Salmi
Journal:  Am J Clin Dermatol       Date:  2021-05       Impact factor: 7.403

Review 4.  Missing Insight Into T and B Cell Responses in Dermatitis Herpetiformis.

Authors:  Esko Kemppainen; Teea Salmi; Katri Lindfors
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

Review 5.  Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease.

Authors:  Timo Reunala; Teea T Salmi; Kaisa Hervonen; Katri Kaukinen; Pekka Collin
Journal:  Nutrients       Date:  2018-05-12       Impact factor: 5.717

Review 6.  The Skin in Celiac Disease Patients: The Other Side of the Coin.

Authors:  Ludovico Abenavoli; Stefano Dastoli; Luigi Bennardo; Luigi Boccuto; Maria Passante; Martina Silvestri; Ilaria Proietti; Concetta Potenza; Francesco Luzza; Steven Paul Nisticò
Journal:  Medicina (Kaunas)       Date:  2019-09-09       Impact factor: 2.430

7.  Non-Biopsy Serology-Based Diagnosis of Celiac Disease in Adults Is Accurate with Different Commercial Kits and Pre-Test Probabilities.

Authors:  Venla Ylönen; Katri Lindfors; Marleena Repo; Heini Huhtala; Valma Fuchs; Päivi Saavalainen; Alex Musikka; Kaija Laurila; Katri Kaukinen; Kalle Kurppa
Journal:  Nutrients       Date:  2020-09-08       Impact factor: 5.717

8.  TG6 Auto-Antibodies in Dermatitis Herpetiformis.

Authors:  Marios Hadjivassiliou; Timo Reunala; Kaisa Hervonen; Pascale Aeschlimann; Daniel Aeschlimann
Journal:  Nutrients       Date:  2020-09-21       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.